Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
News related to:Equillium, Inc · 1 min read
LA JOLLA, Calif., Sept. 16, 2026 /CourierPR/ -- Equillium, a biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders, will participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum. The company’s management team will engage in a fireside chat on Wednesday, September 23, 2026, at 12:00pm EDT.
The event, which is part of Stifel’s annual forum, aims to bring together industry experts, researchers, and investors to discuss the latest advancements in immunology and inflammation. Equillium’s participation is expected to provide insights into the company’s ongoing research and development efforts, as well as its strategic direction in the field.
Equillium, based on its mission statement, is committed to creating highly impactful therapies for patients suffering from severe autoimmune and inflammatory conditions. The company’s involvement in such a high-profile forum underscores its dedication to staying at the forefront of innovation in biotechnology.
The fireside chat will be available for live streaming on the company’s website, with a replay scheduled to be accessible for approximately 45 days following the conference. This opportunity for investors and industry professionals to engage with Equillium’s management team is seen as a valuable platform for networking and gaining deeper insights into the company’s pipeline and future plans.
Equillium’s participation in the forum is part of its ongoing efforts to build relationships with key stakeholders and to share its progress with the broader community. The company’s presence at such events is crucial for maintaining its visibility and credibility in the biotechnology sector, particularly as it continues to develop novel treatments for severe autoimmune and inflammatory disorders.